Arca
Skip to content
Tools
Tools

Fatigue

Drug research and approvals for fatigue: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 357 studies of fatigue are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 357
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 357 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 9

Phase 2 6

Phase 1 or earlier 3

  • DisulfiramAldehyde dehydrogenase inhibitor
  • KetamineGlutamate [NMDA] receptor negative allosteric modulator
  • AspirinCyclooxygenase inhibitor

How its trials ended

1,457 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 237 whose ending is known, 40% met their primary endpoint, 11% missed it and 49% stopped early.

  • Completed, result not reported73550%
  • Ongoing27819%
  • Status unknown20714%
  • Met its primary endpoint957%
  • Stopped: other or unclear654%
  • Stopped: enrollment or feasibility362%
  • Missed its primary endpoint252%
  • Stopped: lack of efficacy5<1%
  • Stopped: sponsor or business decision5<1%
  • Stopped: funding5<1%
  • Stopped: safety1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Apr 24, 2026Randomized double-blind placebo-controlled cross over trial of modafinil to treat fatigue in people with mitochondrial disease.ModafinilResearch Institute of The McGill University Health CentrePending
Mar 7, 2025Modafinil to improve fatiguability (MODIFY): modafinil vs. placebo vanguard randomized controlled trialModafinilOttawa Hospital Research InstituteOngoing
Feb 26, 2024Modafinil and exercise for post stroke fatigue (MODEX)ModafinilUniversity Health NetworkPending
Jan 25, 2023Recovering from COVID19 lingering symptoms adaptive integrative medicine (RECLAIM)OxygenUniversity Health NetworkOngoing
Jun 1, 2022A double blind randomized trial of low-dose naltrexone for post-covid fatigue syndromeNaltrexoneBritish Columbia Womens HospitalOngoing

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Dec 9, 1993Poly I: poly C12UTreatment of chronic fatigue syndromeAIM ImmunoTech Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.